hepatitis%20a%20-and-%20e
HEPATITIS A & E

Hepatitis A route of transmission is through oral-fecal route. While in hepatitis E, aside from the oral-fecal route, it is also transmitted through blood transfusion in endemic areas.

Hepatitis A incubation period is 15-50 days and hepatitis E incubation period is 21-60 days.

Hepatitis A & E viruses cause epidemics.

 

Prevention

PREVENTION & POST-EXPOSURE PROPHYLAXIS OF HEPATITIS A
Patient Group for Whom Prevention or Post-exposure Prophylaxis is Recommended Recommended Prevention or Post-exposure Prophylaxis Regimen
Prevention
Hepatitis A
Susceptible persons traveling to HAV-endemic areas
Household contacts, daycare children & staff
Healthcare personnel & lab researchers potentially exposed to HAV
Patients who will undergo blood transfusion or will receive clotting factor concentrates
Immunocompromised children (suboptimal response)
Men who have sex w/ men (MSM)
Illegal drug users (both injection & non-injection drug users)
Persons w/ chronic liver disease, including persons w/ chronic HBV & HCV infection who have evidence of chronic liver disease
Hepatitis A Vaccine1
Post-exposure Prophylaxis
Hepatitis A
Unvaccinated or nonimmune persons exposed to hepatitis A virus (HAV) through household or sexual contact or by sharing illegal drugs w/ a person who has hepatitis A2
Administer a single IM dose of human immunoglobulin (Ig) as soon as possible but not >2 weeks after exposure
1 Postvaccination serologic testing is not indicated because most persons respond to the vaccine
2 A person who has had 1 dose of hepatitis A vaccine at least 1 month before exposure to HAV does not need Ig
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 23 Aug 2019

Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.

Yesterday
New drug application approved by US FDA as of 01 - 15 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.